RBC Capital analyst Ben Hendrix lowered the firm’s price target on NeueHealth (NEUE) to $7 from $8 and keeps a Sector Perform rating on the shares. The company reported solid Q3 results ahead of expectations and the management maintained guidance, though the firm is reducing its price target as it rolls its valuation out to 2025, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUE: